BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 33693183)

  • 1. Comparative Effectiveness of Angiotensin II Receptor Blockers in Patients With Hypertension in Japan - Systematic Review and Network Meta-Analysis.
    Nakajima T; Oh A; Saita S; Yoshida T; Ohishi M; Nishigaki N
    Circ Rep; 2020 Sep; 2(10):576-586. PubMed ID: 33693183
    [No Abstract]   [Full Text] [Related]  

  • 2. Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis.
    Wang JG; Zhang M; Feng YQ; Ma CS; Wang TD; Zhu ZM; Kario K
    J Clin Hypertens (Greenwich); 2021 May; 23(5):901-914. PubMed ID: 33609077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
    Nixon RM; Müller E; Lowy A; Falvey H
    Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
    Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis.
    Zhang Z; Yang H; Guo H
    Int J Clin Pharm; 2024 Jun; ():. PubMed ID: 38861046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
    Satoh M; Haga T; Hosaka M; Obara T; Metoki H; Murakami T; Kikuya M; Inoue R; Asayama K; Mano N; Ohkubo T; Imai Y
    J Hypertens; 2016 Jun; 34(6):1218-23. PubMed ID: 27027425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
    Stumpe KO
    Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
    Dorosch T; Ganzer CA; Lin M; Seifan A
    Curr Pain Headache Rep; 2019 Sep; 23(11):85. PubMed ID: 31515634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
    Kurtz TW; Kajiya T
    Vasc Health Risk Manag; 2012; 8():133-43. PubMed ID: 22399858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial.
    Weir MR; Wang RY
    J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1_suppl):S217-S222. PubMed ID: 28095219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olmesartan medoxomil: current status of its use in monotherapy.
    Brunner HR
    Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?
    Greathouse M
    Congest Heart Fail; 2002; 8(6):313-20. PubMed ID: 12461321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.
    Simons WR
    Pharmacoeconomics; 2003; 21(1):61-74. PubMed ID: 12484804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Azilsartan on clinical blood pressure reduction compared to other angiotensin receptor blockers: a systematic review and meta-analysis.
    Khan QA; Sharma S; Mulk IU; Li D; Belay NF; Afzal M; Farrukh AM; Asad M; Baqi A; Semakieh B
    Ann Med Surg (Lond); 2024 Feb; 86(2):958-967. PubMed ID: 38333313
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 40.